Spots Global Cancer Trial Database for Expanded Access of Cabozantinib in Medullary Thyroid Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Expanded Access of Cabozantinib in Medullary Thyroid Cancer
Official Title: An Open-Label, Expanded Access Study of Cabozantinib (XL184) in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Study ID: NCT01683110
Conditions
Interventions
Study Description
Brief Summary: The objective of this study is to provide access to cabozantinib for eligible subjects with medullary thyroid cancer (MTC) pending approval of Exelixis' New Drug Application (NDA) by the FDA and commercial availability of cabozantinib.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Stanford, California, United States
, Boston, Massachusetts, United States
, Detroit, Michigan, United States
, Portland, Oregon, United States
, Philadelphia, Pennsylvania, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
